ChromaDex Unveils Niagen+ With FDA Authorization; NRC To Be Available In IV, Shot, And Push Forms At Clinics Nationwide
Portfolio Pulse from Benzinga Newsdesk
ChromaDex has announced the launch of Niagen+, a new product that has received FDA authorization. The product will be available in various forms including IV, shot, and push at clinics nationwide.
June 13, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ChromaDex has launched Niagen+, a new product that has received FDA authorization. This product will be available in IV, shot, and push forms at clinics nationwide, potentially boosting the company's market presence and revenue.
The FDA authorization of Niagen+ and its availability in multiple forms at clinics nationwide is likely to enhance ChromaDex's market presence and drive revenue growth. This positive development is expected to have a favorable impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100